Literature DB >> 10864188

Antibody response to culture filtrate antigens of Mycobacterium tuberculosis during and after treatment of tuberculosis patients.

M S Imaz1, E Zerbini.   

Abstract

SETTING: Many authors have shown rising titres of anti-mycobacterial antibodies after a few months of anti-tuberculosis treatment. This humoral response might persist for years, making the discrimination between current and old disease difficult.
OBJECTIVE: Characterisation of the humoral response to culture filtrates of Mycobacterium tuberculosis before and after treatment of tuberculous patients in order to identify those antigens that could provide information about disease activity.
METHODS: Anti-mycobacterial IgG response was determined during and after treatment of tuberculous patients by ELISA and immunoblot. Serum was taken from 71 active tuberculous patients (59 newly acquired and 12 relapse), 15 old tuberculous patients and 45 nontuberculous control subjects.
RESULTS: By ELISA, antibody response increased after 2 months of treatment. After chemotherapy was completed, the estimated number of antibodies remained at the same level. The level of specific antibodies in patients seems to reach the same level as that of control subjects 3 years after initiation of treatment. In Western blot, although each patient serum had its own characteristic banding pattern, differences between tuberculous patients and control subjects were found in the area below 20 kDa. Serum from tuberculous patients showed high levels of antibodies at the 14 kDa region. After the beginning of treatment, the intensity of the 14 kDa region band and the percentage of positive recognition tended to decrease. Therefore, one year after initiation of treatment, only seven of 13 cases who demonstrated anti-mycobacterial antibodies in ELISA revealed a mild but still positive reaction at the 14 kDa region; this reactivity disappeared 2 years after initiation of chemotherapy.
CONCLUSIONS: The 14 kDa region antigen seems to induce a humoral response that evolves in relation with the disease activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864188

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Comparison of the proteosomes and antigenicities of secreted and cellular proteins produced by Mycobacterium paratuberculosis.

Authors:  Donghee Cho; Michael T Collins
Journal:  Clin Vaccine Immunol       Date:  2006-10

2.  Tuberculosis in elephants: antibody responses to defined antigens of Mycobacterium tuberculosis, potential for early diagnosis, and monitoring of treatment.

Authors:  Konstantin P Lyashchenko; Rena Greenwald; Javan Esfandiari; John H Olsen; Ray Ball; Genevieve Dumonceaux; Freeland Dunker; Carol Buckley; Michael Richard; Suzan Murray; Janet B Payeur; Peter Andersen; John M Pollock; Susan Mikota; Michele Miller; Denise Sofranko; W Ray Waters
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Clinical evaluation of anti-tuberculous glycolipid immunoglobulin G antibody assay for rapid serodiagnosis of pulmonary tuberculosis.

Authors:  R Maekura; Y Okuda; M Nakagawa; T Hiraga; S Yokota; M Ito; I Yano; H Kohno; M Wada; C Abe; T Toyoda; T Kishimoto; T Ogura
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis.

Authors:  Lenka M Pereira Arias-Bouda; Sjoukje Kuijper; Anouk Van der Werf; Lan N Nguyen; Henk M Jansen; Arend H J Kolk
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

5.  Human T cell and antibody-mediated responses to the Mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens.

Authors:  Gilson C Macedo; Adriana Bozzi; Helena Rachel Weinreich; Andre Bafica; Henrique C Teixeira; Sergio C Oliveira
Journal:  Clin Dev Immunol       Date:  2010-12-29

6.  Detection of a combination of serum IgG and IgA antibodies against selected mycobacterial targets provides promising diagnostic signatures for active TB.

Authors:  Dolapo O Awoniyi; Ralf Baumann; Novel N Chegou; Belinda Kriel; Ruschca Jacobs; Martin Kidd; Andre G Loxton; Susanne Kaempfer; Mahavir Singh; Gerhard Walzl
Journal:  Oncotarget       Date:  2017-06-06

7.  A Subgroup of Latently Mycobacterium tuberculosis Infected Individuals Is Characterized by Consistently Elevated IgA Responses to Several Mycobacterial Antigens.

Authors:  Ralf Baumann; Susanne Kaempfer; Novel N Chegou; Wulf Oehlmann; Ralf Spallek; André G Loxton; Paul D van Helden; Gillian F Black; Mahavir Singh; Gerhard Walzl
Journal:  Mediators Inflamm       Date:  2015-08-10       Impact factor: 4.711

8.  Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study.

Authors:  Irene Andia Biraro; Moses Egesa; Simon Kimuda; Steven G Smith; Frederic Toulza; Jonathan Levin; Moses Joloba; Achilles Katamba; Stephen Cose; Hazel M Dockrell; Alison M Elliott
Journal:  BMC Infect Dis       Date:  2015-10-22       Impact factor: 3.090

9.  Screening and assessing 11 Mycobacterium tuberculosis proteins as potential serodiagnostical markers for discriminating TB patients from BCG vaccinees.

Authors:  Guoqiang Zhang; Lingxia Zhang; Mingcheng Zhang; Linlin Pan; Fengyu Wang; Jun Huang; Guoli Li; Jun Yu; Songnian Hu
Journal:  Genomics Proteomics Bioinformatics       Date:  2009-09       Impact factor: 7.691

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.